The collaboration will effectively help optimize the delivery of Beta-C and several other active ingredients into patient’s skin and local tissues.
Canada’s dermatology firm, Crescita Therapeutics Inc. and leading cannabinoid-derived drug provider, Tetra Bio-Pharma’s subsidiary, Tetra Natural Health (NHP) have recently announced an arrangement to develop an enhanced Tetra dermatology portfolio version with the help of Crescita’s branded transdermal delivery technologies, DuraPeel™ and MMPE™ (Multiplexed Molecular Penetration Enhancer).
For the record, beta-caryophyllene (Beta-C) is the primary active ingredient contained in the product portfolio, known to work on Cannabidiol (CBD) 2 receptors. Sources cite that the clinical development and testing methodology made possible by the collaboration will effectively help optimize the delivery of Beta-C and several other active ingredients into patient’s skin and local tissues.
Reportedly, some of Tetra’s dermatology products have already been approved by Health Canada as natural health products which can address several medical conditions such as cold sores, muscle pain, joint pain and hemorrhoids.
Reliable sources claim that the duo has entered into discussions related to Crescita’s contract manufacturing services to manufacture Tetra’s improved product portfolio once favorable results are obtained in the testing and development phases of the collaboration.
According to Nasdaq, Serge Verreault, President & CEO, Crescita, said that the company is delighted to partner with Tetra Natural Health to assist them in the development and evaluation of several enhanced-delivery formats of their topical products.
He said that the company believes that integrating Crescita’s patented DuraPeel and MMPE technologies into its existing formulations, will enable them to significantly enhance the delivery and efficacy of their products which will further help improve outcomes for Canadians suffering from several painful conditions.
Richard Giguère, Chief Executive, Tetra Natural Health, was quoted saying that the new collaborative agreement inked with Crescita will allow them to serve many Canadian patients’ dermatology needs. He said that Crescita owns impressive technology which is likely to set Tetra’s natural health dermatology portfolio apart from its competitors.